Gliclazide Does Not Fully Prevent 2-deoxy-D-ribose-induced Oxidative Damage Because It Does Not Restore Glutathione Content in a Pancreatic β-cell Line

Overview

Journal Oxid Med Cell Longev

Publisher Wiley

Specialties Cell Biology
Endocrinology

Date 2012 Feb 9

PMID 22315655

Authors

Gwanpyo Koh

Min-Kyoung Kim

Eun-Jin Yang

Dae-Ho Lee

Affiliations

Soon will be listed here.

Abstract

We compared the effects of gliclazide, an antidiabetic agent with antioxidant properties, and N-acetyl-L-cysteine (NAC), a glutathione precursor, in protecting against 2-deoxy-D-ribose- (dRib-) induced oxidative damage in HIT-T15 cells. Using trypan blue staining and flow cytometry with annexin V/PI staining, gliclazide treatment slightly reversed dRib-induced cell death and apoptosis, and NAC treatment markedly reduced both measures. Likewise, flow cytometry using DHR 123 staining showed that the levels of dRib-induced reactive oxygen species (ROS) were partially suppressed by gliclazide and completely inhibited by NAC. Using electron spin resonance spectrometry, gliclazide and NAC scavenged hydroxyl radicals generated by Fenton reaction to a similar degree in a cell-free system. NAC, but not gliclazide, completely restored the intracellular glutathione depleted by dRib using monochlorobimane fluorescence and glutathione assays. Thus, gliclazide treatment suppressed dRib-induced oxidative damage in HIT-T15 cells less than NAC did because gliclazide did not restore the intracellular glutathione content as effectively as NAC. In addition, the elevation of intracellular glutathione rather than free radical scavenging might be an important mechanism for protecting against dRib-induced oxidative damage in a β-cell line.

References

Hedley D, Chow S . Evaluation of methods for measuring cellular glutathione content using flow cytometry. Cytometry. 1994; 15(4):349-58. DOI: 10.1002/cyto.990150411. View

Robertson R . Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem. 2004; 279(41):42351-4. DOI: 10.1074/jbc.R400019200. View

Ceriello A . Effects of gliclazide beyond metabolic control. Metabolism. 2006; 55(5 Suppl 1):S10-5. DOI: 10.1016/j.metabol.2006.02.005. View

Harrower A, Wong C . Comparison of secondary failure rate between three second generation sulphonylureas. Diabetes Res. 1990; 13(1):19-21. View

Jennings P, Belch J . Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide. Metabolism. 2000; 49(2 Suppl 1):23-6. DOI: 10.1016/s0026-0495(00)80081-5. View

Jennings P, Scott N, Saniabadi A, Belch J . Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessment. Metabolism. 1992; 41(5 Suppl 1):36-9. DOI: 10.1016/0026-0495(92)90093-p. View

Tanaka Y, Gleason C, Tran P, Harmon J, Robertson R . Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci U S A. 1999; 96(19):10857-62. PMC: 17973. DOI: 10.1073/pnas.96.19.10857. View

Harmon J, Bogdani M, Parazzoli S, Mak S, Oseid E, Berghmans M . beta-Cell-specific overexpression of glutathione peroxidase preserves intranuclear MafA and reverses diabetes in db/db mice. Endocrinology. 2009; 150(11):4855-62. PMC: 2775976. DOI: 10.1210/en.2009-0708. View

OBrien R, Luo M . The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro. Metabolism. 1998; 46(12 Suppl 1):22-5. DOI: 10.1016/s0026-0495(97)90312-7. View

10.

Scott N, Jennings P, Brown J, Belch J . Gliclazide: a general free radical scavenger. Eur J Pharmacol. 1991; 208(2):175-7. DOI: 10.1016/0922-4106(91)90069-t. View

11.

Harrower A . Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications. 1994; 8(4):201-3. DOI: 10.1016/1056-8727(94)90044-2. View

12.

Schmidt M, Greb H, Koliwer-Brandl H, Kelm S, Dringen R . 2-deoxyribose deprives cultured astrocytes of their glutathione. Neurochem Res. 2010; 35(11):1848-56. DOI: 10.1007/s11064-010-0251-y. View

13.

Turner R, Cull C, Frighi V, Holman R . Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281(21):2005-12. DOI: 10.1001/jama.281.21.2005. View

14.

Gerich J . Oral hypoglycemic agents. N Engl J Med. 1989; 321(18):1231-45. DOI: 10.1056/NEJM198911023211805. View

15.

Koh G, Lee D, Woo J . 2-Deoxy-D-ribose induces cellular damage by increasing oxidative stress and protein glycation in a pancreatic beta-cell line. Metabolism. 2009; 59(3):325-32. DOI: 10.1016/j.metabol.2009.07.028. View

16.

Tanaka Y, Tran P, Harmon J, Robertson R . A role for glutathione peroxidase in protecting pancreatic beta cells against oxidative stress in a model of glucose toxicity. Proc Natl Acad Sci U S A. 2002; 99(19):12363-8. PMC: 129450. DOI: 10.1073/pnas.192445199. View

17.

Groop L, Schalin C, Widen E, Ekstrand A, Eriksson J . Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy. Am J Med. 1989; 87(2):183-90. DOI: 10.1016/s0002-9343(89)80695-3. View

18.

Noda Y, Mori A, Packer L . Gliclazide scavenges hydroxyl, superoxide and nitric oxide radicals: an ESR study. Res Commun Mol Pathol Pharmacol. 1997; 96(2):115-24. View

19.

Koh G, Suh K, Chon S, Oh S, Woo J, Kim S . Elevated cAMP level attenuates 2-deoxy-d-ribose-induced oxidative damage in pancreatic beta-cells. Arch Biochem Biophys. 2005; 438(1):70-9. DOI: 10.1016/j.abb.2005.03.018. View

20.

Fico A, Manganelli G, Cigliano L, Bergamo P, Abrescia P, Franceschi C . 2-deoxy-d-ribose induces apoptosis by inhibiting the synthesis and increasing the efflux of glutathione. Free Radic Biol Med. 2008; 45(2):211-7. DOI: 10.1016/j.freeradbiomed.2008.04.017. View